National Cancer Plan

Ashley Dalton Excerpts

Thursday 5th February 2026 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

With permission, I will make a statement on the Government’s national cancer plan for England.

A cancer diagnosis changes you forever. When I was diagnosed with metastatic breast cancer 18 months ago, I did not know whether I would be alive today, never mind standing at this Dispatch Box announcing a national cancer plan, but one year ago almost to the day, the Prime Minister asked me to do just that. Since the Government took office, over 212,000 more people are getting a cancer diagnosis on time, over 36,000 more are starting treatment on time, and rates of early diagnosis are hitting record highs. Despite those vital signs of recovery, though, the NHS is still failing far too many cancer patients and their families. That is why first and foremost, this plan is a break with the failure of the past 15 years.

In 2011, the coalition Government published “Improving Outcomes: A Strategy for Cancer”. That strategy was followed in 2016 by “Achieving world-class cancer outcomes: a strategy for England”. In 2019, the long-term health plan for England made cancer a priority and included a headline ambition to diagnose 75% of cancers at stages 1 and 2. However well-intentioned they were, not one of those strategies has lived up to its promises. Cancer mortality rates in the UK are much higher than in other, comparable countries, while survival rates are much lower. Cancer incidence is around 15% higher than when the 62 day standard was last met, and working-class communities are being failed most of all. The most deprived areas, including rural and coastal communities, often have fewer cancer consultants, leaving patients waiting longer. This all adds up to the chilling fact that someone living in Blackpool is almost twice as likely to die young from cancer than someone living in Harrow. Wherever in our country a person lives, they deserve the same shot at survival and quality of life as everyone else. Wealth should not dictate their health, and neither should their postcode.

Behind these statistics are real people. I have heard from those whose care lacked empathy and dignity, from those whose cancer was missed or whose test results were lost, from those who were passed from pillar to post and kept in the dark about their condition, and from those whose loved ones died before their turn came for surgery because the wait was too long. Those experiences are unacceptable—they are devastating. From day one, I was determined to put their voices front and centre of our plan. Over the past year, we have listened to and learned from cancer charities, clinicians and, most importantly, patients and their families. Every action is a response to someone’s lived experience. Every commitment is a promise to transform someone else’s life. Their stories have become the blueprint to make the biggest improvement in cancer outcomes in a generation.

Three major themes stood out from the 11,000 responses to our call for evidence, some 9,000 of which came from patients and their carers: core performance standards, improved survival, and quality of life after diagnosis. Those are not radical ideas, but unlike previous strategies, this plan is not limited to incremental improvement. Instead, it is an ambitious, bold plan to save 320,000 more lives by 2035, which will be the fastest rate of improvement this century. We will do that by modernising the NHS, harnessing the power of science and technology, putting our patients at the front of the queue for the latest medicines, and helping them to live well after diagnosis, not least for people diagnosed with stage 4, metastatic and incurable cancers—people like me.

How do we get there? We are placing big bets on genomics, data and artificial intelligence, as set out in our 10-year plan for health. We will hardwire the three shifts of our 10-year plan into cancer pathways. First, on moving from analogue to digital, we heard from patients about the importance of clinical trials, so we will make the UK one of the best places in the world to run a trial with a new cancer trials accelerator. We will start people’s care earlier using liquid biopsy tests, which can return results up to two weeks faster than conventional testing. We will harness AI to read scans, plan radiotherapy and identify the right path for each patient. We will harness genomics so that every eligible patient has access to precision medicines. We will harness data to make sure that all metastatic disease is counted properly—starting with breast cancer—so that people with incurable cancer are properly recognised and supported. When people are not counted, they feel like they do not count, but we will end that.

Innovation will also help us fight inequalities and make the shift from sickness to prevention. We will turn the NHS app into a gateway for cancer care. By 2028, it will host a dashboard for cancer prevention, with access to tests and self-referral. By 2035, it will bring together genomic and lifestyle data with the single patient record to advise every patient according to their risk. That will benefit people in rural and coastal communities who can find it difficult to access specialist care simply due to geography.

Finally, we will use the neighbourhood health service to make the shift from hospital to community. That will mean more care, from prehabilitation to recovery support, delivered closer to home. We will help people live well with cancer through tailored support closer to home. People will be given personal cancer plans, named neighbourhood care leads and clear end-of-treatment summaries so that no one feels abandoned after their treatment.

For too long, those with rarer cancers have seen little to no progress for many of their conditions. They told us we need a special focus on these cancers, and our plan sets out how they will benefit from the deployment of genomics, early detection and the development of new treatments. That was asked for by patients and will be delivered by this Government. I pay tribute to my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) for her campaigning in memory of her late sister Margaret. We should also remember that the late Tessa Jowell raised this issue in 2018, and her family have campaigned ever since.

Our plan also gives pride of place for children and young people. We will improve their experience of care at every level, from hospital food to youth worker support and play support. I pay tribute to my hon. Friend the Member for Leyton and Wanstead (Mr Bailey) for his campaigning on that point. Our children and young people cancer taskforce asked for support with travel costs, because when someone’s child has cancer, the last thing they should worry about is how they will pay for their train ticket. Today, I can announce that we will fund those travel costs.

Alongside rare and less common cancers, we will make research for children and young people a national priority. I take this moment to thank the children, young people and families who made up our children and young people cancer taskforce. It was a pleasure and a privilege to meet them earlier this week. I thank the many families and loved ones of people lost too soon who continue to fight to make change for others. I am so grateful to them, and I want people to hear their voices as they read the plan, because it is rooted in the voices of patients, families, clinicians and charities. It will turn cancer from one of this country’s biggest killers into a chronic condition that is treatable and manageable for three in four patients. It delivers the ambition of the 10-year health plan, embodies this Government’s three shifts and sets a clear path towards earlier diagnosis, faster treatment and world-leading survival rates by 2035.

This plan does not belong to the NHS, and it does not belong to the Government; it belongs to us all. We all must play a part in making it work. Over the past year, I have met the patients, families, carers, clinicians, researchers, cancer charities and voluntary groups who all contributed to our plan. This Government is on their side. We wrote this with them, and we cannot deliver it without them. Let us do it together. I commend this statement to the House.

[Madam Deputy Speaker (Judith Cummins)]

I call the shadow Secretary of State.

[Stuart Andrew (Daventry) (Con)]

I thank the Minister for advance sight of her statement. May I say right at the outset that we share the ambition to improve cancer survival and outcomes? Almost every family in Britain has been touched by cancer, and patients deserve timely diagnosis, treatment and proper support. I also recognise the Minister’s personal experience and the commitment that she has clearly brought to this agenda. We on the Opposition Benches wish her every success for the future. I also join her in thanking all those who have taken part in the shaping of this plan. It makes a big difference when we hear the voices of patients and families who have been through these experiences.

The national cancer plan sets out major commitments, including on early diagnosis, improving performance against cancer waiting time standards, the faster set-up of clinical trials, and the national roll-out of targeted lung screening. It also talks about modernising services through technology and innovation. Cancer Research UK has said there is “much to welcome” in the plan, but it is right for it to say that delivery, funding and accountability will determine whether patients see change. Too often, plans sound impressive on paper but fall short when it comes to clear published delivery milestones and accountability. In many respects, this plan mirrors the ambitions of the 10-year NHS plan: it is strong on aspiration, but light on the detail of how change will actually be delivered on the ground. My first question is simple: when will the Government publish clear, funded milestones showing how and when patients will see improvements in the next year or two?

We welcome investment in diagnostics, technology and innovation. It is also right to recognise that this plan builds on the significant expansion of diagnostic capacity delivered by the last Conservative Government, including the roll-out of more than 160 community diagnostic centres. Earlier diagnosis on this scale is only possible because of that foundation, but technology is only meaningful if it translates into real capacity and quicker treatment for patients. That is why radiotherapy matters. Radiotherapy UK is right that it is a core part of modern cancer care, but it relies on up-to-date equipment and a skilled workforce. My second question is this: will Ministers set out how the plan will expand radiotherapy capacity in practice, including equipment replacement and the workforce, so that patients can benefit in reality, rather than the plan just being something written on paper? Are we learning the lessons from the Danish example? They invested in radiotherapy and saw significant improvements over a period of years.

That point brings me on to the workforce. The success of this plan depends on cancer nurses, radiographers, pathologists and oncologists who are already under immense pressure. We have heard big promises before, but less clarity on delivery, so my third question is this: where is the fully funded long-term workforce plan to deliver the staffing needed to expand diagnostic and treatment capacity and to make sustained improvements, including in neighbourhood health centres? Will the Government explain clearly who will staff them and how they will be funded? Blood Cancer UK has highlighted the importance of ensuring that blood cancers are properly recognised in planning and that patients receive consistent support from the point of diagnosis, including access to a named healthcare professional. That underlines why delivery and accountability across the system matter so much to patients.

I also welcome the commitments in this plan to children and young people. I pay tribute to my hon. Friend the Member for Gosport (Dame Caroline Dinenage), who I know did some incredible work in this area. Having worked in children and young people’s hospices, I will never forget the journey that those children and their families go on, and I am really grateful to the Government for having a big section on that in the plan.

My fourth question is about life after—and at the end of—treatment. The plan rightly talks about improving quality of life and support after treatment, including personalised support and rehabilitation; we all want people to live longer, but for many patients and their families, hospice and palliative care are essential. Yet hospices across the country are under severe pressure, with many now in crisis, exacerbated by recent Government tax rises hitting staffing and running costs. Hospices are also notably absent from today’s statement. Will the Government urgently convene a crisis meeting with the hospice sector and set out what immediate steps they will take to stabilise services and expedite delivery of the palliative care plan?

We will support any serious, deliverable reforms that improve earlier diagnosis, speed up treatment, strengthen the workforce and improve patient experience. But we will also hold Ministers to account on turning long term ambitions into real improvements now, because we want to see patients getting the care that they need.

[Ashley Dalton]

I thank the right hon. Member for his statement and questions, and particularly for his personal wishes.

Overseeing delivery is absolutely crucial. It is great that we have written a plan, but what matters is delivering it. We started delivery even before we had finished writing this plan; we are not waiting. We have already put £200 million directly into cancer via cancer alliances. We have recruited 2,500 more GPs. We have already put in place 28 cutting edge radiotherapy machines and are rolling out lung cancer screening. We have opened more community diagnostic centres at evenings and weekends. We said we would deliver 2 million more appointments; we have already delivered 5 million more appointments. And we have put £25 million into the National Institute for Health and Care Research’s brain tumour research consortium.

Steps are already being taken, but it is really important, as the right hon. Member points out, that we are held to account and that people keep our feet to the fire on delivery. That is why we are setting up a brand new cancer board of charities and clinicians, which will oversee the delivery of this plan and keep our feet to the fire.

On workforce, we know how important it is to make sure that the cancer workforce is grown and developed, not only in terms of numbers but in having the resources and the support to use their skills to the utmost. The workforce plan that the Government are developing will also include cancer and will be published this spring.

I was delighted to hear the right hon. Member mention rare cancers and children and young people. This is the first ever cancer plan with a chapter on rare cancers, and the first ever cancer plan with a chapter on children and young people, and I am really proud of that.

On radiotherapy, as I said, we have invested £70 million into 28 new linear accelerator—LINAC—radiotherapy machines. We have also listened to stakeholders in the radiotherapy community. We are investing in new technology, including those radiotherapy machines, and in AI to assist the oncology workforce to reduce the time it takes to plan and then deliver treatment. By April next year, we will streamline the process to make it easier for radiotherapy centres to use cutting edge stereotactic ablative radiotherapy—SABR—which is crucial to many patients. We will also ensure that the payment system associated with this treatment incentivises rapid adoption.

The right hon. Member mentioned hospices, something that I know is very close to his heart and his experience. We are delivering the biggest investment in hospices in a generation. We have provided £100 million to upgrade buildings, facilities and digital systems, and we are giving a further £26 million to children’s and young people’s hospices, ensuring that they can continue offering specialist, compassionate support. More broadly, we are developing a palliative care and end of life modern service framework for England. That is currently being developed alongside our stakeholders, with a planned publication date of autumn 2026.

I hope that addresses most of the issues raised by the right hon. Member, but I am more than happy to speak with him further after the debate.

[Mr Clive Betts (Sheffield South East) (Lab)]

I really welcome this plan, and the efforts of my hon. Friend the Minister and right hon. Friend the Secretary of State in putting it together. I will just raise one credit and one request to go a bit further.

First, when I had my cancer treatment eight years ago, I thought I knew my way around the NHS, but it is a completely confusing organisation for anyone involved in it. One thing that really helped me was having a specialist nurse appointed at the beginning. That specialist nurse got my chemotherapy ready on a Monday before I came down to London, and then on a Thursday when I came back. That sort of organisation and help is vital, so I really welcome that proposal.

Secondly, when I had my stem cell transplant for myeloma, my own stem cells were harvested and used, but many young people with complicated blood disorders need stem cells to be donated. So will the Minister work with the Anthony Nolan trust—I am chair of the all-party parliamentary group on stem cell transplantation and advanced cellular therapies—to ensure that more young people donate their stem cells so that other young people can have a life to look forward to?

[Ashley Dalton]

I thank my hon. Friend for his question, for his expertise and for all that he has shared from his experience to help us develop this plan. I note how important specialist nurses are, but we are also doing more to help people navigate the NHS. I know exactly what it is like; I think I have in my Filofax—I am that retro!—about 38 email addresses and phone numbers of the various people I have to contact in order to project manage my treatment. We are going further and ensuring that the NHS app can handle all that information. Cancer patients will have the ability in their hands, or in their pockets, to manage scans, appointments and test results directly through the NHS app.

I am delighted to say that my hon. Friend the Minister for Technology, Innovation and Life Sciences is already looking at the issues that my hon. Friend the Member for Sheffield South East (Mr Betts) raises around blood products and donations, and is working with the Anthony Nolan trust on those. I will be more than happy to work with my hon. Friend further on those issues.

[Madam Deputy Speaker (Judith Cummins)]

I call the Liberal Democrat spokesperson.

[Helen Maguire (Epsom and Ewell) (LD)]

I thank the Minister for advance sight of the statement and for her personal experience that has gone into this plan. After the Conservatives failed to invest in our NHS, it is no surprise that cancer survival in the UK is still around 10 to 15 years behind leading countries, with worse survival rates for some cancers than Romania and Poland. I am therefore pleased that this Government listened to my hon. Friend the Member for Wokingham (Clive Jones) and brought this national cancer plan to life, because cancer touches everyone.

One of my residents, a mum with a young family, discovered a lump in her breast. Despite attending the one stop breast clinic on four separate occasions, it took two horrendous years for her to be diagnosed with breast cancer. When she was finally diagnosed, the cancer was aggressive and required a mastectomy, chemotherapy and radiation therapy. That is why I welcome the Government’s target on meeting all cancer wait time standards by 2029, but the aim to halve the backlog in three years’ time is not ambitious enough. Will the Minister go further and back a Liberal Democrat plan to write into law a guarantee for all cancer patients to start treatment within 62 days from urgent referral?

The focus on ending delays in cancer care is a step forward, but funding 28 new radiotherapy machines is not enough when the treatment is so cost effective and successful. We need to end radiotherapy deserts, so will the Minister extend her ambition to 200 extra radiotherapy machines?

The Minister says that the plan will turn the NHS app into a gateway for cancer care, but how will she support older people and the digitally excluded? The plan promises to drive up productivity, end the postcode lottery, expand NHS diagnostic capacity, introduce personalised cancer plans and more. That is optimistic and will require more investment to increase NHS capacity, but without clear funding and capacity building plans, is it realistic?

Labour was right to put patients at the heart of this plan and incorporate the Liberal Democrat’s calls for a specialist cancer nurse for every patient. We costed for 3,000 extra cancer nurses; how many additional cancer nurses does the Minister believe are needed?

Finally, will the Minister confirm that the plan’s annual summary of progress will be reported in the House for Members to scrutinise?

[Ashley Dalton]

We listen to a lot of people on the need for a cancer plan. I want to take this opportunity to say that our friend Nathaniel Dye, who sadly died last week from stage 4 bowel cancer, challenged my right hon. Friend the Secretary of State to bring forward a cancer plan when we were in opposition. The Secretary of State made that commitment, and we have brought forward the plan 18 months after coming into government.

The hon. Lady mentions the NHS app, which we understand is not necessarily relevant for people who are digitally excluded. One reason we are bringing that forward is to open up capacity within the rest of the system, so that those who can use digital tools can do so. That will free up capacity for the one-to-one, face-to-face support that many people need, but every cancer patient will get support under this plan, whether that is through the app or through their named lead clinical specialist in their neighbourhood, who will support them throughout the process, including after treatment. We are working with NHS England to identify the appropriate number of people for the cancer workforce, and we will be able to announce more about that as the workforce plan develops.

[Ben Goldsborough (South Norfolk) (Lab)]

Three hundred and eighty-eight days ago, the words were uttered to me, “You have stage 2C skin cancer.” I have had 388 days of scans, operations and treatments that did not need to happen, because preventive care could have stopped me getting skin cancer. That is why today’s statement is so important. Action 30 in the plan focuses on melanomas and skin cancers, and it means a huge amount to me personally that the Government have taken this issue so seriously. My ask of the Government is that when we undertake the reviews into UV and preventive skincare, we should look at the examples of Australia and other countries that take this seriously, so that we can ensure that our young people and adults know how to stay safe in the sun.

[Ashley Dalton]

I commend my hon. Friend for the work that he is doing in this area while going through treatment for skin cancer. Action 30 is really important, and we are also committing in this plan to tackling under-age sunbed use. We are committing to look at what more we can do to combat dangerous sunbed use, and to promote prevention when it comes to skincare in the sun. We will explore what more we can do about that, and I look forward to working with my hon. Friend to do so.

[Sir Edward Leigh (Gainsborough) (Con)]

While cancer incidence in Lincolnshire is about average, premature mortality is higher than average, and we only have to look at a map of England to see the north-south divide and the rural-urban divide. I want to ask about prostate cancer. I do not want to get into a debate about national screening, because that has been well aired, but it is not generally known by men that any man over the age of 50 can go to his GP and demand a prostate-specific antigen test. It seems to me that, as part of this programme, we should encourage all men every year to ask not just for a PSA test, but for a general blood test. Women should do similar. Irrespective of national screening programmes, everybody should do that, given that survival rates for conditions such as prostate cancer are incredibly high if there is early detection. Is that not something that we should be encouraging?

[Ashley Dalton]

I agree with the right hon. Member that prevention is absolutely key. We cannot prevent all cancers, but we can do much to prevent cancers from being caught late and to get to them when they are more treatable. We encourage all eligible people to access the tests and screening that are available to them. Through the new NHS app, each individual will be able to get a personalised risk factor to identify what they may be at risk of, and to nudge them towards which tests and screenings they should ask their GP for. That is something that we are looking to develop for all cancers, including prostate cancer. We are also expanding access to the life-extending prostate cancer drug abiraterone—I had to practise saying that; I can say mine, which is capecitabine. That will get thousands more men effective treatment earlier, which can significantly improve their chances of long-term survival. Through this plan, we intend to prevent and catch cancer early. Included in the plan is raising awareness of cancer across all communities to ensure that people access the screening and early tests that they are entitled to.

[Josh Fenton-Glynn (Calder Valley) (Lab)]

This Tuesday would have been my brother Alex’s 54th birthday, but sadly we lost him to cancer last year. That is why I am really proud that this plan will revolutionise treatment, care and research into cancer, as well as focusing on rare cancers, such as the one that killed my brother. Although I pay tribute to the doctors and nurses who were responsible for looking after my brother, I think it is fair to say that sometimes people with cancer get treatment but not care. One of the most exciting things about this plan is the section on getting cancer treatment to fit around people’s lives, because Alex spent too long waiting for letters and being his own advocate—a professional patient. Will the Minister please explain what more we are going to do to ensure we not only treat the symptoms but care for the patient?

[Ashley Dalton]

I commend my hon. Friend for the campaigning that he has done in his brother’s name in the area of rare and less survivable cancers, including brain tumours. We are putting patients at the centre of this plan, which says not only that every patient will have a personalised cancer treatment plan, but that patients will be at the heart of deciding those plans. Alongside their clinicians, they will have a role to play in deciding what treatment works for them. I know personally what that means. When I got my diagnosis, the immediate suggestion was that I would have intravenous chemotherapy. I was able to engage with my oncologist and say, “I’m not sure that that works for my lifestyle. I want to be able to live my life.” We were able to work together to find the right treatment that fits in with my lifestyle, and which allows me to come to work and do this job. That is what we want for every single cancer patient in this country. Their treatment should be about not just keeping them alive, but extending and maintaining their quality of life.

[Sir John Whittingdale (Maldon) (Con)]

The league table of NHS trusts shows that the percentage of patients starting treatment for cancer within 62 days in Mid and South Essex is 21%, which puts it bottom of 121 trusts. Can the Minister say what additional help will be given to the Mid and South Essex NHS trust to recruit the additional staff it needs, and to help it to meet the targets that she has just set out?

[Ashley Dalton]

The trust to which the right hon. Gentleman refers is the trust where I had my primary cancer treatment, so I am acutely aware of the challenges. We have set a really clear and simple ambition: to get cancer patients the timely care they need, and to meet all waiting time standards by the end of this Parliament. That means that by March 2029, 80% of patients will get a diagnosis or the all-clear within 28 days, and 85% of patients will start their treatment within 62 days of referral. Some people have asked me why the figure is not 100%. It is not possible to make it 100%, because not everybody’s cancer is simple or easy to identify, and sometimes it takes longer. We want to ensure that the only reason for delays beyond 62 days is the complexity or specifics of someone’s cancer, not the inability of a trust to meet the targets.

We are going to cut waiting times by giving trusts and cancer alliances detailed practical information and granular data on individual cancer types so that we can highlight real-time pathway insights through a federated data platform, and by streamlining the cancer metrics so that we can shine a light on unwarranted variation in care. We are providing information and best practice, thereby taking the best of the NHS to the rest of the NHS. We are linking up professionals and clinicians across the UK, so that they can share their best practice. Trusts can help and support each other to reach the targets.

[Peter Prinsley (Bury St Edmunds and Stowmarket) (Lab)]

What a brilliant plan, and I congratulate the Minister on bringing it to the House this afternoon. However, cancer trials need clinical academics, and we have a crisis in clinical academic recruitment, retention and funding. Does she agree that we must find ways to encourage young clinicians into academic and research roles?

[Ashley Dalton]

Yes, I do agree, and we are working on that. We are establishing the cancer trials accelerator programme to increase the speed, scale and reliability of cancer trials, and we will use the new health tech access programme to make it quicker. We will also be supporting the development, through the workforce plan, of all the clinicians required, including academics.

[Pippa Heylings (South Cambridgeshire) (LD)]

This weekend, I got the devastating call about my brave and wonderful sister Dawn, loving mother and carer to Ella, who, after a dash to A&E, was diagnosed with late-stage pancreatic cancer and given just three to six months to live. What links less survivable cancers is their late diagnosis. Does the Minister agree with my amazing sister Dawn and me that we need to be more proactive about early diagnosis of less survivable cancers, such as through annual screening of those with a family history or high-risk genetic factors, to improve the ability to detect and remove tumours early and improve the five-year survival rates—sadly, hers is not—to over 50%?

[Ashley Dalton]

I offer the hon. Member my deepest condolences on the news that she has shared with the House. I share her concern that we have to reach others. Some less survivable cancers can be tackled if they are caught early, and we have specifically committed in the plan to reducing significantly the number of rare and less survivable cancers that are diagnosed in an emergency setting, which she described as happening to her family. Primary care is where most people first raise concerns. GPs rarely see rare cancers, because they are rare, so we are rolling out AI-driven decision support tools to help GPs think cancer sooner, think cancer earlier and make decisions about referral more quickly.

[Rachael Maskell (York Central) (Lab/Co-op)]

I, too, thank the Government for bringing forward this cancer plan. I visited York Against Cancer’s Leveson centre last Friday, and I really welcome the holistic care it gives to cancer patients. I want to highlight prevention. We know that four in 10 cancers are preventable, and the right interventions can be transformative, particularly for people from low socioeconomic communities. Will the Minister talk a little bit more about the public health approach that will be taken? In York we have seen a 30% cut in our public health budget over the past 10 years, which means less resource is available to prevent cancers.

[Ashley Dalton]

Prevention is a key part of this plan. As I have mentioned, we are doing an awful lot on that—for instance, on illegal under-age sunbed use. We are also eliminating cervical cancer through HPV vaccination and tackling obesity. Fundamentally, we are creating the world’s first smoke-free generation with our groundbreaking Tobacco and Vapes Bill. We do not ignore the communities hit the hardest, and the cancer alliances are promoting new schemes to enable young people to catch up on vaccinations, such as HPV, that they may have missed. We are tackling harmful alcohol consumption by introducing new mandatory health warnings and nutritional information on alcohol labels. We have reformed the public health grant in recent years—we have wrapped it up—and many places have seen an overall increase. We are also giving local authorities more flexibility in how they use their public health grant and, for the first time in many years, multi-year settlements so that they can plan.

[Several hon. Members rose—]

[Martin Vickers (Brigg and Immingham) (Con)]

Further to the exchanges about radiotherapy, I understand that the national figure for access to radiotherapy is 53%, which itself does not seem particularly high. However, the figure for my Brigg and Immingham constituency, which falls in the Yorkshire and the Humber region, is only 35%. Could the Minister give some assurance to my constituents about progress on increasing that figure, and when does she think we can reach the national average?

[Ashley Dalton]

Through the spending review, providers have been allocated £15 billion in operational capital for local priorities and £5 billion to support the return to constitutional standards on radiotherapy. Responsibility for purchasing new machines sits at local level, and we expect local systems to continue to invest in new machines to meet the ambitious targets and to meet their local needs.

[Pam Cox (Colchester) (Lab)]

I really welcome the national cancer plan and the Minister’s clear personal determination to bring it to fruition. Does she agree that local innovations are going to play a key part? Such an innovation is the prehabilitation service in Colchester, which gets patients ready for treatment before their treatment begins. Would she and her team like to visit that and other local services to see the impact for herself?

[Ashley Dalton]

Yes, I do agree. This plan is about ensuring that wraparound care is there from the very beginning, and I would be more than delighted, if my diary allows, to visit the service that my hon. Friend mentions.

[Mr Will Forster (Woking) (LD)]

Yesterday, for World Cancer Day, I hosted here in Parliament Walk the Walk, a national charity that I am proud is based in my Woking constituency. It has raised over £146 million to fight cancer and to help people live healthy lives. I am sorry that the Secretary of State is no longer in his place, but will the Minister ask him to choose his favourite bra and join me on a Walk the Walk—with he in his favourite bra and me in mine—so that we can raise awareness for “mannogram” testing? Will she also ensure that mammogram testing is extended to the under-40s and the over-70s?

[Ashley Dalton]

Ministers quite like making promises from the Dispatch Box on behalf of our Front-Bench colleagues, but in this case I think I will just gently encourage my right hon. Friend the Secretary of State to join the hon. Member, if he is able to do so—I look forward to seeing the photographs.

We are exploring opportunities for breast cancer screening. There are difficulties in early screening because of dense breast tissue, but we are expanding screening where it provides support. In particular on breast screening, we are monitoring the emerging evidence from BRAID—breast screening risk adaptive imaging for density—trials, which target programmes at women with greater risk. We are also considering the findings from the £11 million EDITH—early detection using information technology in health—trial, testing how cutting-edge tools can be used to catch breast cancer cases earlier, particularly in younger women, like me, for whom a mammogram was not successful because of dense breast tissue.

[Harpreet Uppal (Huddersfield) (Lab)]

I join others in thanking the Minister for all the work on the national cancer plan. Last week I was lucky enough to visit the brand-new NHS community diagnostic centre on the national health innovation campus at Huddersfield University. Diagnostic radiographers are being trained on the second floor of that building. I also welcome the work of Calderdale and Huddersfield NHS foundation trust, which is ranked as one of the best performing trusts in the country for meeting cancer waiting times. How will we learn from that best practice across the country?

[Ashley Dalton]

I thank my hon. Friend for highlighting such amazing work happening in her constituency. From the very beginning, we have said that this Government’s approach is to take the best of the NHS to the rest of the NHS. Using the NHS app and the new national co-ordination of activities, we hope to share some of that best practice a lot more widely.

[Greg Smith (Mid Buckinghamshire) (Con)]

I very much welcome the plan. I see the Minister’s commitment to it, and in the interests of all our constituents, I absolutely hope that it works and comes through. In the last Parliament, I did a lot of work on the all-party parliamentary group on minimally invasive cancer therapies—the group no longer exists—which, notwithstanding the commitment to innovation and technology that the Minister has outlined, is one area I have not heard much about. Could she outline to the House how this plan will bring through faster, and on a less of a postcode lottery basis, the new minimally invasive therapies?

[Ashley Dalton]

Harnessing technology right across the cancer landscape is what this plan is about. Where it is appropriate for less invasive treatments to be used, we are looking to explore how we can roll them out across the country, regardless of postcodes. Lots more people are surviving cancer with treatment, but what is important is that the side effects of invasive cancer treatment can be significant—I know: I have several of them—so, where possible, we want to use innovative, less invasive treatments so that people can live longer, more fruitful and less painful lives.

[Amanda Hack (North West Leicestershire) (Lab)]

I thank the Minister for her powerful statement. There are clearly differences in cancer treatment depending on where someone lives, whether a rural or coastal community. My semi-rural constituency sits on the edge of three hospital trusts, leading to difficulties such as those highlighted by a constituent who attended my coffee morning earlier this week. She spoke of the difficulties she faces in getting consistency in her cancer treatment, as she sees a Leicestershire GP but gets care from the University Hospitals of Derby and Burton NHS foundation trust. Will the Minister set out more on the neighbourhood element of the treatments addressed in the national cancer plan?

[Ashley Dalton]

The cancer plan sets out policies that have been developed specifically to tackle geographic inequalities in cancer care, with increased medical training places in rural and coastal areas, improved data transparency on the quality of care and performance of trusts, and investment in cancer alliances that proactively support local communities, while treatment support from neighbourhood care leads will help people to navigate their cancer pathways. Cancer outcomes should not be dependent on someone’s location in the country, so we are working to bring postcode lotteries to an end. We are using the NHS app so that patients can manage their cancer treatment themselves. More widely—this relates to what we announced in the summer for the 10-year health plan—single patient records will also allow patients to access services more easily, particularly across different ICBs.

[Liz Saville Roberts (Dwyfor Meirionnydd) (PC)]

Does the Department have a procurement strategy to ensure security of supply of medical radioisotopes, which are so critical for diagnosis and treatment? Could the Minister provide details of the co-operation and assessments made by her Government with the Welsh Government on Project ARTHUR, the isotope reactor scheme at Trawsfynydd?

[Ashley Dalton]

I understand that the right hon. Lady has already met the Minister for health innovation, my hon. Friend the Member for Glasgow South West (Dr Ahmed), to discuss these issues, and that he will continue to work with her on them and to explore them further.

[Fleur Anderson (Putney) (Lab)]

I congratulate the Minister on this excellent plan and invite her to congratulate Young Lives vs Cancer, which has long campaigned for the travel fund for children and young people with cancer. I have joined the charity in its campaigning and am absolutely delighted to see the travel fund in place. Can she confirm that she will continue to work with Team Margot and Anthony Nolan to increase stem cell donation from people from ethnically diverse communities, where there is a shortage, in memory of Margot, who died from leukaemia aged two?

[Ashley Dalton]

Yes, I can confirm that we will continue to work with cancer charities. I am particularly delighted with the work we have done with Young Lives vs Cancer and other young people’s cancer charities, which have brought amazing insight and basically written the chapter on children and young people with cancer with the team. I would be delighted to continue that work.

[Clive Jones (Wokingham) (LD)]

I was the first MP in this Parliament to call for a national cancer plan back in October 2024, so I congratulate the Secretary of State and the Minister for publishing the plan. There are some good things in it: the concentration on children and young people’s cancers; the concentration on rare and less-survivable cancers; and more desperately needed screening. Targets in the plan are also to be welcomed, but if they are to be met, there is a need for workforce expansion, especially in oncology, pathology, radiology and clinical nurse specialists. The extra cash that the Secretary of State has obtained for the plan from the Treasury is not enough to achieve all his ambitious plans right away. How will the Secretary of State and the Minister get from the Chancellor the money needed to make this plan a success?

[Ashley Dalton]

As I have already stated, the workforce is key. The workforce plan will be published in spring this year. As of November 2025, there are now 70% more staff in the key cancer professions of clinical oncology, gastroenterology, medical oncology, histopathology, clinical radiology, and diagnostic and therapeutic radiology than in 2010—we are starting to make inroads, although we know there is further to go. We will be driving that forward through this plan and the workforce plan, due in the spring.

[Luke Myer (Middlesbrough South and East Cleveland) (Lab)]

I pay tribute to my constituents, including Melissa from Guisborough, who campaigns on lobular breast cancer, Georgia from Hemlington, who campaigned on cervical cancer, and Peter from Coulby Newham, who campaigns on prostate cancer. What assurances can the Minister give them that resources will be put into communities like mine to tackle health disparities and make sure that everyone, no matter where they live, can get the cancer care they deserve?

[Ashley Dalton]

I commend the campaigning work of my hon. Friend’s constituents and say to them that their voices run through this plan; they have written this plan with their campaigning activity as much as we have. The James Cook university hospital in my hon. Friend’s constituency has had funding for two new LINAC machines—medical linear accelerators—which is helping to ensure that people get access to treatment. The plan will ensure that postcode and geography will not get in the way of the treatment people receive, and I look forward to working further with my hon. Friend and his constituents on how we can make that a reality.

[Terry Jermy (South West Norfolk) (Lab)]

I congratulate the Minister on this excellent piece of work. It is crucial to my residents in west Norfolk, where we have statistically the worst hospital in the country at the Queen Elizabeth in King’s Lynn—not in a big city, but in a rural part of west Norfolk. I ask the Minister to reassure my residents that unlike what happened under the previous Government, who created a postcode lottery in which many more rural communities missed out, this will be a truly national cancer plan that covers all parts of our great country.

[Ashley Dalton]

We recognise that the provision of cancer services varies significantly across the country. This plan sets out how we will end that variation by bringing healthcare to the community and ensuring that everyone, no matter their postcode, has access to high-quality cancer care. I want to assure everybody that cancer outcomes should not be dependent on someone’s location in the country and that we will make timely access to high-quality diagnostic and treatment services a reality for anyone and everyone who needs it.

[Tessa Munt (Wells and Mendip Hills) (LD)]

I welcome the statement and the plan, and salute the Minister’s bravery; I wish her very good health.

My constituents do not get a particularly good deal: when measured against the 62-day target, 47% meet the target for radiotherapy, 62% for drugs and 73% for surgery. However, looking at just the first treatment masks the true picture, as a combination of treatments is often crucial to survival, and if people wait six months for their second treatment, it is really poor. Will the Minister consider bringing in measurement of secondary treatments? We know that radiotherapy can reduce a tumour and that surgery comes later, but if someone has to wait six months for surgery, they are in trouble.

[Ashley Dalton]

Yes, we are aware of that. We are looking at the existing metrics and at what we can do to improve them to ensure that they are actually making a difference to people’s outcomes.

[Josh Newbury (Cannock Chase) (Lab)]

In welcoming the national cancer plan, I want to pay tribute to my phenomenal Auntie Hillary, who passed away in September 2020. A GP practice manager, her selfless focus on ensuring that her elderly and vulnerable patients were okay during the first lockdown meant that she put off getting the early symptoms of her own cancer checked out; she got rapid treatment, but sadly it was too late. Will my incredible hon. Friend confirm that the direction and investment set out in this plan will ensure that hundreds of thousands of families a year will be celebrating all-clears, not mourning losses?

[Ashley Dalton]

I thank my hon. Friend for his question and offer my condolences on the loss of his Auntie Hillary. Yes, this plan is designed to ensure that an extra 320,000 people at the end of the course of the plan will have had their lives saved or be living well with cancer after their five-year diagnosis. We want to make sure that everybody gets that opportunity, regardless of where they live.

[Adrian Ramsay (Waveney Valley) (Green)]

I welcome the national cancer plan, and in particular the Minister’s focus on early diagnosis and ending the scandal of postcode inequality. Cancer Research UK has highlighted that limited funding could significantly impact on progress against the plan, so can the Minister assure us that she is allocating funding in order to meet her own rightful ambitions, and say whether she is engaging with Cancer Research UK and others in the sector on the funding that is needed?

[Ashley Dalton]

Yes, I can confirm that, but it is not always about throwing extra money at things. It is about using the resources that we have in a better, more targeted way to be more impactful. I have worked with Cancer Research UK from day one of developing this plan and it has run right the way through it. We continue to work with the organisation as we move forward to make the plan a reality.

[Peter Swallow (Bracknell) (Lab)]

This week marks 17 years since my mum died of lung cancer. She was just 58, and I was just 15. Last week, when I visited a local lung cancer screening service in Bracknell and heard how it is using AI to speed up diagnosis, it was personal. Can the Minister say a bit more about what we are doing to roll out schemes such as that to make sure that more families like mine do not have to suffer the loss of a loved one to this terrible disease?

[Ashley Dalton]

I thank my hon. Friend for his question. Lung cancer has impacted on my family as well. Yes, we will be rolling out lung cancer screening nationwide by 2030, because we know that it has a huge impact on outcomes. I have seen how amazing the AI tools are at identifying discrepancies in lung CT scans. I found out that I had an untapped talent, as I was quite good at identifying those discrepancies as well. AI means that we can catch lung cancers sooner. They are often not caught until they are at stage 3 or 4. Using AI means that we can get them at stage 1 or 2, we can treat people early and we can save lives.

[Ayoub Khan (Birmingham Perry Barr) (Ind)]

I welcome the Minister and thank her for presenting this national cancer plan. Her conviction, enthusiasm and passion for the subject are clearly seen from the Dispatch Box. She talks about regional disparity, but we also have disparity within constituencies. My constituency of Birmingham Perry Barr operates 20% below the national average, so I am pleased that the Minister will be addressing that. It has been reported that 64 radiotherapy machines are running over their 10-year lifespan, which has cost the NHS 87,000 appointments. We know that we have 28 new machines. What will the Government do to get more new machines?

[Ashley Dalton]

As I have set out, we have already invested £70 million in the new LINAC machines, and we are using AI to support oncologists to use those machines more effectively. Through the spending review, we are providing £15 billion in operational capital for local priorities. It is down to local ICBs and local trusts to identify what they need and what they want to purchase in their areas, but we are providing the support and guidance to help them do that.

[Lewis Atkinson (Sunderland Central) (Lab)]

I wish to thank NHS cancer teams in Sunderland for doing such incredible work in my constituency. Other Members have mentioned the unacceptable variation in NHS performance against waiting times, and I commend the Minister’s focus on that. Can she say a little about the variation in waiting times by tumour site? In November last year, 82% of skin cancers were tret within 62 days, but for gynaecological cancers, the figure was only 58%.

[Ashley Dalton]

This is a key issue. Some cancers are an awful lot easier to get at, and so they are a lot easier to diagnose sooner. We are looking at how we can roll out screening wherever appropriate and increase access to tests such as liquid biopsies, which I talked about in the statement, so that people can get their diagnoses sooner.

[Ann Davies (Caerfyrddin) (PC)]

I thank the Minister for her announcement today. At the end of the day, cancer will affect one in two of us—those are the statistics now. May I also thank colleagues for highlighting the difference in treatment between rural and urban areas? In Wales, we do not even have a plan yet. Without urgent action, there will continue to be inequalities and long waiting times for the people of Wales. That is why, with input from the European Cancer Organisation, Plaid has developed its own cancer plan. What does the Minister make of the decision of Welsh Labour colleagues not to implement a plan in Wales, and why do we not have parity with the rest of the country?

[Ashley Dalton]

I can assure the hon. Member that we are working with our Welsh counterparts to make sure that there is equity of access to resources and to information, and we will continue to do so.

[Ms Julie Minns (Carlisle) (Lab)]

The reality is that if someone lives in a big city with access to a university teaching hospital, their access to cancer treatment will be different from those who live in a town or small city like Carlisle, where we face challenges in recruiting and retaining specialist consultants. Does the Minister agree that this plan, combined with the pioneering approach to training doctors at the new Pears Cumbria School of Medicine, will begin to fix those inequalities that my constituents experience?

[Ashley Dalton]

That is absolutely the case. This plan will support people in my hon. Friend’s constituency by expanding access to community diagnostic centres and personalised neighbourhood-based cancer care. We are also focusing on recruiting more cancer specialists for rural and coastal areas, and are supporting that through the workforce plan.

[Chris Murray (Edinburgh East and Musselburgh) (Lab)]

I strongly welcome the Minister’s statement, which I found quite emotional. I know that many of her friends are pleased to see her making it today. She said that cancer mortality is higher and survival is lower in Britain compared with other European countries. What that means is that cancer patients such as Charlotte Montague have to go abroad to seek treatment themselves and then come back and advocate for that treatment to be incorporated in the NHS. What will the plan do to bring Britain more in line with European countries, so that people do not need to go abroad to seek treatment?

[Ashley Dalton]

We are learning from comparable countries. By looking at what they have achieved, we have begun to put together this plan. We want to make Britain the place to come to for clinical trials of new innovative treatments. We are looking not only to learn from other countries about the treatments they already offer, but to have our own home-grown new treatments and innovations through our clinical trials accelerator in the UK.

[Sarah Smith (Hyndburn) (Lab)]

I congratulate my hon. Friend on this ambitious and much-needed plan. She met my constituent, Lorraine. Lorraine lost her daughter Milly and set up Milly’s Smiles, a charity that offers to families arriving at hospitals across the country a welcome pack of essential items to help them on their journey. I know that she will welcome the reference to improving non-clinical and supportive care for children in the plan. Does my hon. Friend agree that it is only by working together with charities, families, researchers and the health service that we will deliver on this plan for everybody across the country?

--- Later in debate ---

[Ashley Dalton]

I absolutely agree with my hon. Friend. It was my pleasure to meet Lorraine. I will, if I can, say very quickly that when we met her, she was explaining to officials how she did not have what she needed for her daughter when they were sent to the specialist care unit straight from A&E. One official said, “Why couldn’t you go and get what you needed?” We all looked at him and said that nobody was going to leave that child. That is why this cancer plan recognises the importance of wraparound care for children and young people, so that parents can support their families best.

[Douglas McAllister (West Dunbartonshire) (Lab)]

I congratulate the Minister on this excellent and ambitious plan. If we are to achieve its targets, improvements need to be made on delivering earlier and better diagnosis, particularly for cancers with extremely low survival rates, such as acute myeloid leukaemia, which has a five-year survival rate of just 22%. In my West Dunbartonshire constituency, 46 people have lost their lives to leukaemia in the past five years. I have lived with leukaemia over the past 18 years. Can the Minister confirm that, as part of this plan, improvements will be made in the survival rate for acute myeloid leukaemia?

[Ashley Dalton]

As my hon. Friend knows—I do not need to tell him this—brain tumours, leukaemia and other less stageable cancers cannot be assessed in the usual way, so we need different measures to understand how early they are being caught. That is why this plan commits to the regular publication of data on emergency cancer diagnoses as a key indicator, exposing where these cancers are picked up too late so that we can drive earlier detection and focus attention where it is most urgently needed.

[Anna Dixon (Shipley) (Lab)]

My hon. Friend the Minister saw yesterday at first hand the amazing care and support that Maggie’s centres provide to not only patients and survivors but their families. What role will charities and voluntary organisations such as Maggie’s play alongside the NHS in delivering improved care for cancer patients and their families?

[Ashley Dalton]

Organisations such as Maggie’s play a crucial role. That is why we chose to launch our national cancer plan at a Maggie’s centre yesterday. We cannot do this alone. Charities, support organisations, family groups, and the tiny little charities run from a back bedroom by the family of somebody who suffered a very rare cancer, all have a role to play in how we bring forward the cancer plan. I am most proud of the fact that this is not the Government’s cancer plan but the country’s cancer plan. Every voluntary-sector community organisation and charity has a role to play, and I look forward to working further with them all.

[Linsey Farnsworth (Amber Valley) (Lab)]

I thank the Minister for this excellent plan. In 1989, my wonderful mother Margaret passed away from bowel cancer. She died about six weeks after she was diagnosed. She had not wanted to go to her GP because she did not want to be a burden on the already overstretched NHS. Will the Minister join me in encouraging anyone who fears that they might have bowel cancer to see their GP, and will she provide assurances to those people regarding screening and early diagnosis for bowel cancer?

[Ashley Dalton]

We have extended NHS bowel cancer screening to cover people from the age of 50, and between now and 2028 we will be increasing the sensitivity of the faecal immunochemical test—otherwise known as the FIT test—and rolling it out nationally by 2028. Combined with increased uptake, that will deliver 17,000 earlier diagnoses by 2035 and save almost 6,000 lives.

[Dr Scott Arthur (Edinburgh South West) (Lab)]

This plan gives so many people so much hope, and it was great to see it delivered with so much passion and energy. It is clear why the Minister is really respected by many people right across the sector. I have to say that I have never seen a statement delivered with so much energy—more of that, please. I also thank the Minister for her leadership and for supporting my Rare Cancers Bill from her very first day in office. She has found a place in the plan for my Bill, and I really do thank her for that.

I have three questions. Will rare cancers be recorded and reported separately as part of the plan? What influence will the cancer board have over the delivery of the plan? I think that point is quite important. Lastly, others have spoken about community organisations. In Gorgie in Edinburgh South West, we have the House of Hope, led by Lisa Fleming. She delivers a fantastic support service for women who have a breast cancer diagnosis. The next time the Minister is in Edinburgh, will she visit Lisa and her team?

[Ashley Dalton]

I commend my hon. Friend on all the work he has done, particularly on the Rare Cancers Bill, which the Government are delighted to support. Not only does this plan have the first ever chapter on rare and less-survivable cancers, but we will be appointing the first ever clinical lead for rare cancers, whose job it will be to make sure that rare cancers are properly counted, registered and that we continue to deliver in this area. I would be delighted to visit the House of Hope next time I am in Edinburgh.

National Cancer Plan

Ashley Dalton Excerpts

Wednesday 4th February 2026 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

The national cancer plan is published today, World Cancer Day. Building on the foundations set out in the 10-year plan for the NHS, it sets out how we will drive improvements in cancer care across England. One in two people in this country will get cancer in their lifetime, and this plan provides a clear and focused approach to deliver better outcomes for patients, focusing on earlier diagnosis, faster treatment and better survival rates. We will work to end the postcode lottery—everybody should have access to prompt and effective care and treatment no matter where they live or what their background is.

The plan includes actions and commitments which clearly show how we will achieve our goal of 75% of people surviving cancer for five years or more by 2035, making England a world-leader for cancer survival. Actions in the plan will cover a range of areas including:

Improving NHS cancer performance: We are committed to meeting the cancer waiting time standards by the end of this Parliament. By March 2029, 80% of patients getting a diagnosis or all-clear within 28 days of an urgent suspected cancer referral (faster diagnosis standard), 85% of patients will start their treatment within 62 days of referral, and 96% of patients will start treatment within 31 days of a decision to treat them. We will increase productivity in diagnostics by using digital pathways and the latest technology, and use innovation to speed up treatment decisions.

Early diagnosis, lung cancer screening and treatment: More people are surviving cancer than ever before, but progress has slowed over the last decade, and England remains behind other comparable countries. We need to catch cancer earlier and faster because we know early diagnosis is key to cancer survival. We will expand screening where evidence supports this—including completing the roll out of lung cancer screening by 2030. In addition, we will continue community testing to identify people at higher risk of cancer including fibro-scans for people with cirrhosis and fatty liver disease, as well as invest in the latest tech and AI to spot cancers earlier. We will also increase access to the best innovative cancer treatments as they become available.

Prevention: Many cancers are preventable, which is why we will stop as many cancers as we can by cracking down on illegal underage sunbed use, eliminating cervical cancer through HPV vaccination, as well as tackling obesity and creating the world’s first smoke-free generation. We will also complete a national roll-out of self-testing to women who have not otherwise taken up the offer for cervical screening by 2029. In addition, we will increase awareness of cancer risk factors, and of cancer symptoms.

Living well: Cancer care will be designed around patients’ lives, with every patient sitting down with their care team and getting a personalised cancer plan and named clinical nurse specialist or other named lead to support them through diagnosis and treatment. By 2028, patients will also be able to manage screening invitations, appointments and treatment plans through the NHS app. We will also move more cancer care out of hospitals and into local neighbourhood settings, with patients getting a named neighbourhood care lead to co-ordinate their care and support after treatment.

Children and young people with cancer and their families will get better support, with a guarantee that travel costs do not leave parents out of pocket and create a barrier to accessing NHS care and providing full wraparound care, including psychological support to children with cancer.

Ending the postcode lottery for cancer care: No matter where people live, they should have access to high-quality, specialist care, and also to all the incredible breakthroughs in cancer care we are seeing through the NHS, such as robotic surgery, using genomic testing to assess risk, create targeted treatments, and replace invasive biopsy with faster blood tests across the country.

Inequalities: We will tackle inequalities in cancer mortality. Some places in England, including Blackpool, Knowsley and Kingston upon Hull have an age-standardised premature cancer mortality rate twice as high as the best-performing area. People from poorer parts of the country are more likely to be diagnosed late and less likely to get the best care, while people with disabilities, LGBT+ people, and people from some ethnic groups are less likely to access screening and clinical trials. Solving this is a priority for this plan.

Research and innovation: We will provide strategic leadership across the lifetime of the plan to ensure we are world leaders in cancer research and innovation. Our priorities for research are aimed at increasing cancer survival, as well as achieving better performance and providing excellent quality of life. We will speed up implementation of technology proven to improve cancer outcomes, as well as accelerating access to new tech via our new national HealthTech access programme. We will also establish a cancer trials accelerator programme to increase the speed, scale and reliability of cancer clinical trials—more broadly we will make cancer trials more accessible by making it easier for people to join them locally, for example via their own GP.

Rare cancers: Patients with rare cancers will also benefit from a move to specialist multidisciplinary teams, that cover multiple providers. This will allow them to benefit from the input of specialist centres and so access to the best evidence-based care. We will reduce the number of rare cancers, including brain tumours, being diagnosed in emergency settings. To hold us accountable, and to marshal progress, we will designate a new national lead for rare cancers with a mandate to provide clinical advice and support delivery of these goals.

This plan was developed in partnership with cancer charities, clinicians and most importantly patients who have shared their own experiences. Our call for evidence received over 11,000 responses, and the main messages we heard were that patients want quicker diagnosis; to know they are being offered the latest and most innovative treatment backed by the latest research; and to be supported to live well with cancer. Our plan sets out how we will deliver these improvements.

The national cancer plan will provide a basis for England being a world leader in cancer survival and improving quality of life for those with cancer in this country over the next decade. By focusing on patients and what they need, we can build on improvements of recent years and capitalise on new innovations to allow more people to survive cancer.

[HCWS1306]

Respiratory Syncytial Virus Vaccination: Older Adults

Ashley Dalton Excerpts

Monday 2nd February 2026 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I am today announcing that the year-round vaccination programme to protect older adults against respiratory syncytial virus (RSV) will be extended from 1 April 2026 to also include those aged 80 years and older, and all residents in care homes for older adults, supporting the 10-year health plan ambition to shift from sickness to prevention.

RSV is a common respiratory virus that can cause severe illness, especially for young infants and older adults who are at greater risk. That is why, in September 2024, we introduced new RSV vaccination programmes in England for adults who were aged 75 to 79 years old on 1 September 2024 and those subsequently turning 75, and for pregnant women from 28 weeks gestation to protect their baby during the first months of life. The decision to offer NHS vaccinations to protect these groups against RSV was based on the latest independent expert advice from the Joint Committee on Vaccination and Immunisation (JCVI) at that time. When advising the introduction of these programmes, the JCVI noted that an extension would be considered when there was more certainty about the real-world impact of the programme in 75 to 79-year-olds and the level of protection offered by vaccination in those aged 80 and over.

The JCVI has continued to review the latest evidence and advised in June 2025 that all older adults aged over 75 years should be eligible for an RSV vaccination on the NHS, as well as all residents in a care home for older adults, regardless of their age. The Committee also advised that RSV vaccines could be administered concurrently with covid-19 vaccines.

His Majesty’s Government have accepted the JCVI’s advice, and the UK Health Security Agency are working with NHS England to ensure that newly eligible individuals will be offered an RSV vaccination from 1 April 2026. This means that anyone who is eligible for both the RSV programme and the spring 2026 covid-19 campaign will be able to get both vaccines at the same appointment, which will improve convenience and help maximise uptake.

The RSV vaccination programme has already had a positive impact, leading to a 33% reduction in RSV-related hospital admissions in 75 to 79-year-olds in winter 2024/25, only months after being introduced, while uptake was still rising. A recent publication in The Lancet Infectious Diseases on a UKHSA and NHS collaboration has shown that the vaccine is over 80% effective in preventing admissions due to RSV chest infections.

I am delighted to say that nearly 2 million RSV vaccinations have now been given to older adults who are currently eligible for the programme. This extension will build on that success, by providing protection for even more people at most risk of RSV, which will save more lives and further reduce RSV-related hospital admissions during the winter months.

[HCWS1294]

National Cancer Plan: Care and Early Diagnosis

Ashley Dalton Excerpts

Monday 26th January 2026 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

The Department of Health and Social Care will soon publish the national cancer plan. While more people survive cancer than ever before, progress has slowed over the last decade and England remains behind other comparable countries with working-class communities being failed most of all. This plan will change that.

The provision of cancer services varies significantly across the country. We will work to end the variation and ensure that access to the best cancer diagnosis, treatment and care is possible for everyone.

The national cancer plan will include a set of policies specifically focused on tackling geographic inequalities in cancer care, including:

More cancer care medical training places will be allocated to rural and coastal areas, particularly in areas where there are high numbers of vacancies, or areas with poor performance.

Improved scrutiny and support of cancer services, including increased data transparency on the quality of care and performance to drive up standards across the country. Where people live should not determine whether they get high-quality treatment when they need it.

Patients to get access to cutting-edge early cancer detection technologies regardless of where they live, as NICE begins to assess technology as well as medicines, which, if approved, would be available on the NHS in the same way that already applies to medicines.

Cancer alliances will receive funding and work proactively with local communities and providers to improve early diagnosis rates, including for rarer or less survivable cancers. They will focus on increasing awareness of cancer symptoms, supporting primary care to spot signs of cancer early, and reducing the gap in screening uptake between the most and least deprived areas, with particular efforts to reach ethnic minority and underserved communities.

Further to this, we know that early diagnosis is crucial for improving survival for cancer, for all cancers, including bowel cancer, which is the fourth most common cancer in the UK, impacting 40,907 people in 2023.

Which is why the national cancer plan will include actions to ensure more bowel cancers are caught at an earlier stage, rolling out changes to our bowel cancer screening programmes that are expected to save more than 5000 lives by 2035.

The NHS bowel cancer screening programme offers people aged 50 to 74 screening every two years, faecal immunochemical test kits are sent to people’s homes.

The NHS in England is improving this offer by rolling out increased sensitivity in bowel cancer screening, the programme will lower the threshold from 120 ug/g to 80 ug/g to bring the sensitivity in line with Scotland and Wales. When fully rolled out from 2028, this is expected to catch cancer at an earlier stage for over 600 people per year, treating it faster and saving lives.

Going further, we will roll out letters and invitations on to the bowel cancer screening programme via the app. This will make it easier for individuals to access screening programmes, and give patients control over their health.

The national cancer plan, which will be published shortly, will provide further details of how we will seek to improve early diagnosis of all cancers, and deliver high-quality cancer care to everybody, no matter where they live.

[HCWS1271]

Prostate Cancer: Access to Treatment

Ashley Dalton Excerpts

Monday 19th January 2026 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

Today I am pleased to update the House on significant progress in improving treatment options for men with prostate cancer across England.

This Government are committed to improving cancer survival rates. Too many families across the country are affected by late diagnosis, unequal access to treatment, and variation in outcomes, and we are determined to change that. Our national cancer plan for England will set out how we will transform outcomes for cancer patients and improve their experiences of treatment and care.

That is why I am delighted to inform the House that for the first time, thousands of patients in England with prostate cancer will be able to receive the drug abiraterone, as the NHS expands access to this important treatment. Around 2,000 men diagnosed in the last three months with non-metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men each year are expected to become eligible for the drug, given in combination with prednisolone.

NHS England has been able to expand access to the drug for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll this out last year.

Clinical research shows benefits for patients at earlier stages of the disease. Trials have demonstrated a six-year survival rate of 86% for men taking abiraterone compared with 77% for those receiving standard treatment—hormone therapy with or without radiotherapy. This represents a substantial improvement in outcomes for thousands of families affected by prostate cancer.

The NHS already commissions abiraterone, now available as a lower-cost generic medicine, for advanced prostate cancer, following the commissioning policy introduced in December 2024. Today’s important announcement extends these benefits to patients at an earlier stage of their disease.

I also want to acknowledge the important role of our partners, who have campaigned extensively on this issue and worked closely with NHS England to support this roll-out.

This decision marks a major step forward in our ongoing work to improve cancer outcomes, ensure earlier access to effective treatments, and support men and their families across England.

[HCWS1248]

Food Standards Agency: Scientific Advisory Committees

Ashley Dalton Excerpts

Wednesday 14th January 2026 Written Statements

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

The Food Standard Agency’s independent scientific advisory committees ensure that the agency’s decisions and advice are grounded in the best scientific evidence. The SACs are essential for protecting public health, maintaining food safety standards, and ensuring consumer confidence by embedding science into every aspect of FSA decision making.

Earlier this year, the Cabinet Office undertook a review of arm’s length bodies in line with the aims of the Government plan for change. As part of the recommendations of this review, four of the FSA’s SACs that were previously classified as advisory non-departmental public bodies will be reclassified as departmental expert committees.

The committee on toxicity of chemicals in food, consumer products and the environment advises the FSA, the Department of Health and Social Care, and other Government Departments and agencies on matters concerning the toxicity of chemicals.

The advisory committee on the microbiological safety of food advises Government on questions relating to microbiological issues and food.

The advisory committee on novel foods and processes advises the FSA on matters pertaining to novel foods, traditional novel foods, genetically modified foods and feed, and novel food processes including food irradiation.

The advisory committee on animal feeding stuffs advises on the safety and use of animal feeds and feeding practices, with particular emphasis on protecting human health, and with reference to new technical developments.

All four committees will continue to maintain their current remit, secretariat and membership to allow the continuity of their work and secure their critical functions, with no disruption to their operations or expert advice.

[HCWS1241]

Oral Answers to Questions

Ashley Dalton Excerpts

Tuesday 13th January 2026 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

I also put on record my condolences to the family and friends of Colin Pickthall, the former Member for West Lancashire. As the current Member for that seat, it is my privilege to build on his legacy.

We are committed to furthering investment to unlock new treatments and improve outcomes for brain cancer patients, including by investing in cutting-edge equipment to improve access to samples for research. Individual pathology services in England maintain their own standard operating procedures, and they outline local capabilities and practices, but we are continuing to invest in England’s pathology networks to deliver productivity and transformation improvements.

[Mrs Hodgson]

I welcome the Government’s focus on improving survival rates for cancer, particularly in the forthcoming national cancer plan. Will the Minister agree to attend the campaign for Owain’s law event here in Parliament on 3 February and meet the families, who will have travelled from across the country to brief Members of this House on the urgent importance of fixing the current tissue freezing postcode lottery?

[Ashley Dalton]

We are determined to ensure that everyone who receives a brain tumour diagnosis, regardless of where they live, has access to the latest treatment options. I look forward to meeting Owain’s wife, Ellie, later this month to hear more about their story and the next steps on this topic.

[Paul Waugh (Rochdale) (Lab/Co-op)]

6. What steps his Department is taking to improve maternity care.

--- Later in debate ---

[Mr Jonathan Brash (Hartlepool) (Lab)]

7. What steps he is taking to improve access to tissue freezing for brain cancer patients in Hartlepool.

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

As previously stated, we are boosting investment to unlock new treatments and improve outcomes for brain cancer patients, including investing in cutting-edge equipment to improve access to samples for research. Each pathology service in England maintains its own standard procedures for tissue freezing, which inform local capabilities and practices, and we are investing in England’s pathology networks to deliver productivity and transformation improvements.

[Mr Brash]

I thank the Minister for her answer, and for her positive response during a recent Westminster Hall debate on this issue. As she will recall from that debate, my constituent Trevor Jones died in September last year from glioblastoma. His widow, Samantha, learned only later that life-extending treatment options might have been available had his brain biopsy not been stored in paraffin blocks, but instead been flash frozen. Will the Minister recommit to examining how flash freezing can be made standard practice for brain biopsies across the NHS, and will she meet me and Samantha to discuss a way forward?

[Ashley Dalton]

As my hon. Friend rightly points out, I was privileged to answer for the Government in the Westminster Hall debate last week on this very issue, and I vividly remember Trevor’s story. Last week, I did commit to exploring current arrangements for tissue freezing options and the options for change, and I recommit to doing that today. I would be more than happy to meet him and his constituent to discuss this further.

[Aphra Brandreth (Chester South and Eddisbury) (Con)]

8. When he plans to publish the NHS 10-year workforce plan.

--- Later in debate ---

[Jo Platt (Leigh and Atherton) (Lab/Co-op)]

10. What steps his Department is taking to improve ADHD services.

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

We know that many people with suspected ADHD—attention deficit hyperactivity disorder—experience severe delays in accessing assessments. That is not right. We want people with ADHD to receive the right support in their communities. Our medium-term planning framework sets out expectations for local areas to improve access to ADHD services. The independent review into prevalence and support for mental health conditions, ADHD and autism will work with people with lived experience to identify challenges and solutions. The final report is due to be published in summer and will build on the independent ADHD taskforce report, which we welcome.

[Jo Platt]

I declare an interest as the chair of the all-party parliament group on ADHD. ADHD providers estimate that untreated ADHD could cost the economy £11.2 billion over the next decade, largely due to avoidable impacts on justice, employment, education and health. Will the Minister commit to ensure that people with ADHD receive the support they need to succeed, and will she work with the APPG to develop strategies that will help individuals to reach their full potential?

[Ashley Dalton]

Through the medium-term planning framework, which we published in October 2025, we set out those expectations. We will continue to work with trusts to develop them to make sure that people with ADHD, or suspected ADHD, get the support they need. I am more than happy to meet the APPG to discuss these matters further.

[Tim Farron (Westmorland and Lonsdale) (LD)]

Roughly 50% of the young people on the books of child and adolescent mental health services in south Cumbria have ADHD or autism. The integrated care board provides no funding whatever to acknowledge that. That is a huge burden on those young people and their families. It stops them getting back into school and so on, but it is also a burden on all the other young people waiting for treatment for things like eating disorders. Will the Minister pay personal attention to this—obviously, it is her ICB as well—to make sure that children with autism and ADHD are properly supported through our CAMHS services?

[Ashley Dalton]

As it is the ICB shared by my constituency, I am equally concerned. This will be explored as part of the review and I am more than happy to ask the Minister responsible to contact the hon. Gentleman further on how we can take that forward.

[Dr Neil Hudson (Epping Forest) (Con)]

11. What assessment he has made of the potential impact of the Government’s house building targets on the availability of primary care services in Epping Forest constituency.

--- Later in debate ---

[Matt Bishop (Forest of Dean) (Lab)]

Parents supported by Harry’s Pals, a small charity, consistently describe the fragmented and emotionally exhausting system of accessing support for children with life-limiting conditions. Will the Secretary of State commit to exploring a dedicated national support pathway for parent carers, including better access to counselling and respite, and will he meet me and Hayley Charlesworth, the founder of Harry’s Pals, who is watching at home today with Harry, to discuss how we can better support families in the Forest of Dean and nationally?

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

Local authorities must assess disabled children’s social care needs and provide respite care, including funding short breaks where appropriate. We are currently developing an all-age palliative care and end-of-life care modern service framework, and will consider the issue of emotional and practical support, including for parents who are carers, as part of that work. My hon. Friend the Minister for Care chairs a cross-Government meeting with Ministers from the Departments for Work and Pensions, for Business and Trade and for Education, to consider how we can provide care as we improve recognition and support. I would be happy to meet my hon. Friend and the founder of Harry’s Pals.

[Lisa Smart (Hazel Grove) (LD)]

My local mental health trust is commissioned to deliver just 100 autism assessments and 88 ADHD assessments per year. The team is led by Clare, a constituent from Marple. There are approximately 1,600 people on the waiting list for ADHD alone—that is a 12-year waiting list. That is driving constituents to seek private diagnoses, but their GPs then refuse to sign up to a shared care arrangement, as the numbers just do not add up. What plans do the Government have to review the shared care protocols so that they work for patients and GPs?

Advanced Brain Cancer: Tissue Freezing

Ashley Dalton Excerpts

Wednesday 7th January 2026 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It is a pleasure to serve under your chairmanship, Mr Western. I thank my hon. Friend the Member for Caerphilly (Chris Evans) and all other hon. Members for their contributions, many of which were deeply personal and moving. I thank them all for their courage and soft-heartedness, and for bringing such compassion and insight to this debate.

Let me say how sorry I was to hear about the loss of Owain at the age of just 34. His story reminds us that many people lose their lives to brain cancer very shortly after diagnosis, and we are determined to do all we can to change that. I extend my deepest sympathies to his wife Ellie, who is here today, and his daughter Amelia. I would be honoured to meet Ellie and my hon. Friend to hear more about her and Owain’s story.

Just yesterday, I was here for a debate on less survivable cancers. These debates and the petition show how much progress on cancer matters to Parliament and the public. My hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) said that debates on brain cancer are a bit like buses: there are none for ages, then suddenly three at once. I want to acknowledge that her work has led to the higher profile for such debates in Parliament, more of which are taking place. I thank and commend her for her efforts in this field.

My hon. Friend the Member for Caerphilly raised incredibly serious issues about how informed consent, tissue freezing and innovation are impacting patients. I will take those points in turn. I will primarily address the context in England, although I acknowledge that areas of this policy apply across the UK. On informed consent and tissue storage, as a cancer patient myself, I find it very troubling when patients say they have not been informed about their tissue storage, as campaigners have reported. I completely understand why the Owain’s law petition calls for people to be properly informed about the choices available to them. Let me be clear: patients must always be fully informed about their rights, options and choices regarding the storage and future use of their tissue samples.

The Human Tissue Authority was established in 2004 to oversee and licence organisations in the removal, storage and use of human tissue in England, Wales and Northern Ireland. Under the Human Tissue (Quality and Safety for Human Application) Regulations 2007, consent must be sought to collect human tissues and cells that are to be used in patient treatment. The Human Tissue Authority ensures compliance against those regulations as part of its standards, inspection and licensing regime.

Consent should be sought in line with the suitable treatment options available to individual patients, which would be determined by their clinicians. That requirement extends to the collection of tumour samples that are to be used as the starting material in the manufacture of cancer vaccines. The Government expect establishments to be held to the highest standards to ensure appropriate and ethical use of human tissue. I understand that my hon. Friend is meeting with the Human Tissue Authority to discuss this matter further, and I know that he will keep me closely in the loop on that.

Owain’s law also asks for every NHS hospital to freeze suitable brain tumour tissue to allow patients to benefit from emerging cancer treatments. Individual pathology services in England have their own processes, known as standard operating procedures, for fresh freezing of tissue samples. NHS procedures mirror local capabilities, which means the capacity for fresh freezing often depends on the availability of neurosurgery services in the local area.

The human tissue regulations were introduced due to concerns that pathologists were retaining human tissues without appropriate consent. Any changes will need to be carefully considered by the Government. However, as was requested by my hon. Friend the Member for Caerphilly and the hon. Member for Strangford (Jim Shannon), I am happy to liaise with the devolved Governments on this issue, and I commit today to further exploring the current arrangements for freezing tissues and the options for change, particularly for brain tumour tissues.

Beyond improving access to emerging treatments through freezing, we know that the most effective way to improve survival rates from cancers, including brain cancers, is to catch them early. That is why we have agreed around £600 million of capital investment in diagnostics for this financial year. Over £100 million will go to histopathology services, automation and digital diagnostics to improve pathology laboratories.

[Dame Siobhain McDonagh]

I apologise for challenging the Minister’s assertion, but in the case of glioblastoma, it really does not matter how early it is detected; the consequence is the same. It is a stage 4 tumour that is going to kill the person and the average life expectancy is nine months.

[Ashley Dalton]

I note my hon. Friend’s clarification, but with that in mind, we do know that it is important to diagnose all cancers as quickly as possible, and the diagnosis of brain cancers is equally important so as to start treatment as quickly as possible. To that end, the Chancellor announced further investment in diagnostics at the autumn statement as part of a £6 billion capital investment to deliver constitutional standards.

On genomics, I met the chief scientific officer for genomics yesterday to discuss how we ensure that the UK remains a world leader in genomics—which we are—and that we can apply genomics to improve cancer outcomes. We hope that our investment in diagnostics and pathology will mean that, in future, patients such as Owain will access a greater range of treatment options.

My hon. Friend the Member for Caerphilly and Ellie are entirely right to raise the importance of innovation, particularly for less survivable cancers such as brain cancer. The Government are proud to support the Rare Cancers Bill introduced by my hon. Friend the Member for Edinburgh South West (Dr Arthur). Next Friday, Baroness Elliott will move its Second Reading in the other place.

We will go even further to ensure that all patients with brain cancer have access to cutting edge clinical trials, innovation and lifesaving treatments. As part of our action, the National Institute for Health and Care Research announced the pioneering brain tumour research consortium to accelerate research into new brain tumour treatments across the UK. The NIHR is backing the consortium with an initial £13.7 million and more money to come this year. The world-leading consortium aims to transform outcomes for adults and children who are living with brain tumours and for their families, ultimately reducing the number of lives lost to cancer. As I confirmed yesterday, I will write to my hon. Friend the Member for Mitcham and Morden in detail regarding access to funding. I am happy to commit to seeking information and exploring how we can make access to funding much clearer and more transparent.

I am pleased to confirm that the national cancer plan for England will be published in just a few short weeks, in early February. It will focus on rarer cancers, including brain cancer, and will include further details on how we will improve outcomes and work with stakeholders such as the Tessa Jowell Brain Cancer Mission to do so. The plan will detail further action to speed up diagnosis and treatment in England, ensuring that patients have access to the latest treatments and technology and ultimately driving up survival rates.

[Jim Shannon]

I thank the Minister for her comprehensive reply to all our questions. In my contribution, I mentioned that Queen’s University Belfast and the Belfast health and social care trust are doing a pilot scheme, which I hope will benefit England, Scotland and Wales. Can the Minister ask her Department’s civil servants to take that on board?

[Ashley Dalton]

I am happy to confirm that I will ask officials to look into that, and to give me some advice on that pilot and on having a conversation with those running it about what we could learn from them. I thank the hon. Member for raising that question.

I will close by paying tribute to our late colleague and Member of the Senedd, Hefin David. Through tireless campaigning, he brought Owain’s story to the Senedd. My hon. Friend the Member for Caerphilly has now brought it to this place and I thank him for that. I look forward to working with him and other hon. Members to make 2026 the year that we shift the dial for patients with brain cancer.

Less Survivable Cancers

Ashley Dalton Excerpts

Tuesday 6th January 2026 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It is a pleasure to serve under your chairmanship, Mr Efford. I thank you and other Members for persevering despite my slightly tardy arrival, which was due, ironically, to the somewhat unpredictable effects of cancer chemotherapy. I am well, however, and have enjoyed the debate immensely.

Before I begin, I pay tribute to all our NHS staff, our care workers and everyone serving our hospices for their work over the Christmas and new-year period. I am grateful to the hon. Member for Wokingham (Clive Jones) for securing this debate, and for doing his bit to keep up morale at the Royal Berkshire hospital on Christmas eve. I thank all Members for their contributions, and acknowledge all their personal stories and the stories they shared of their constituents. Such a wide range of issues has been raised; I will endeavour to respond to all questions, but given the time pressure, I will follow up in writing to any Members whose questions I do not cover.

I will address each of the issues raised by the hon. Member for Wokingham in order. He is right that progress has been uneven across different types of cancer, and that less survivable cancers can be difficult to identify as the symptoms may mirror those of a host of other illnesses. To boost the diagnosis of cancers that are harder to catch at an earlier stage, we have rolled out the non-specific symptom pathways, with 115 NSS services now live. NSS pathways provide a referral route for patients whose symptoms do not fit under a specific cancer pathway. They are making diagnosis smoother and faster for patients whose symptoms are not as clear.

The Government are proud to support the Rare Cancers Bill introduced by my hon. Friend the Member for Edinburgh South West (Dr Arthur). Baroness Elliott will move its Second Reading in the other place on Friday next week.

As a cancer patient myself, I was proud to stand on a manifesto to tackle the biggest killers. My right hon. and learned Friend the Prime Minister reaffirmed that pledge just over a year ago, through our plan for change. Although the all cancer survival rate is the best it has ever been, less survivable cancers have just a 16% five-year survival rate, accounting for 67,000 deaths a year. And demand is rising: each day there are around 13,000 urgent referrals for suspected cancer. That is up almost 3,000 a day since 2019.

My officials, including those leading on the national cancer plan, are carefully considering every one of the APPG’s recommendations. Although I cannot go into detail today, I assure Members that rare and less survivable cancers will feature heavily in the new cancer plan. The Government are asking the NHS, charities and all my colleagues in this place to join in a new national effort, spearheaded by the national cancer plan, which we will publish in just a few short weeks, in early February. I can confirm that there is no truth in the rumour that it is being delayed to March. The plan will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care. We want patients to have access to the latest treatments and technology, and to receive the highest quality of care.

We made genomics one of the five big bets in our 10-year plan for health, setting out how we will harness it to create a genomics population health service and support innovation. In July last year, we launched the groundbreaking national inherited cancer predisposition register, so that we can keep track of people with genes that put them at risk. That brings me to a wider point about diagnostics and primary care. We have introduced Jess’s rule, named after Jess Brady, to prompt GPs to investigate further when a patient presents with the same symptoms or concerns more than twice. We have also boosted community diagnostic centres and invested an extra £889 million in general practice. We are committed to ensuring that GPs have the right training and systems to identify cancer symptoms, and we will continue to support the use of clinical decision support tools.

On research and innovation, the Department of Health and Social Care invests over £1.6 billion a year in research through the National Institute for Health and Care Research. At over £141 million in the last financial year, cancer research is a major area of NIHR spending. Just last month, the NIHR launched a pioneering new £13.7 million brain tumour research consortium to accelerate research into new treatments.

On the question from my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh), I understand that the NIHR chief executive officer, Professor Lucy Chappell, has recently written to her, and I will follow up in writing to respond to my hon. Friend’s question and to explain the process of submitting a bid to the NIHR in detail.

In 2024, the NIHR and the Office for Life Sciences announced nearly £11 million to support the further testing of innovations to help to increase the early detection and diagnosis of cancer. That includes funding for research into the new breath test for multiple gastrointestinal cancers and to look at how we can roll it out in primary care.

People watching at home might be thinking, “Well, what happens with all this research?” So let me briefly give a real-world example of implementation: the Cytosponge is a simple test that can identify conditions that are a precursor to oesophageal cancer. The NIHR, alongside Cancer Research UK, funded research into the development of this “sponge on a string”. This year will see a new NHS pilot of its use in high street pharmacies, supporting the shift in the delivery of care from hospitals to community as part of our 10-year health plan.

The Government are developing a palliative care and end-of-life care modern service framework, with publication planned for spring this year. The framework will align with the ambitions of the 10-year health plan, which prioritises shifting care out of hospitals and into community settings to ensure personalised, compassionate support for individuals of all ages and their families.

The Government were elected on a manifesto to tackle the biggest killers, including cancer. I am proud to stand here today, after 18 months, and say that we can see some green shoots of recovery across the health service, with 135,000 more cancer diagnoses within the 28-day target. That is partly driven by over 100 community diagnostic centres opening at evenings and on weekends, and new surgical hubs to treat people faster.

With the publication of our national cancer plan, 2026 could be a decisive year for cancer care. I look forward to working with the hon. Member for Wokingham, the APPG, my hon. Friend the Member for Edinburgh South West and all other Members to make sure that we keep our momentum into the new year and bring about real change.

Therapeutic Play and Children’s Healthcare

Ashley Dalton Excerpts

Tuesday 6th January 2026 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It is a pleasure to serve under your chairship, Mrs Harris. I thank my hon. Friend the Member for Leyton and Wanstead (Mr Bailey) for securing this debate on such an important topic. I am grateful to him for sharing Hari’s story, and to Hari and Sarah for making the trip to Parliament. I have always believed in bringing patient voices to the heart of what we do in Parliament, and I hope they both leave safe in the knowledge that this Government are listening.

I strongly agree with what hon. Friends have said about the relationship between play and medicine. I volunteered in a healthcare setting as a play worker many moons ago, but more than 30 years later, the important impact of that work has stayed with me. Play and medicine are not in competition, and it is disappointing that Sarah had to fight so hard for play to remain an essential part of Hari’s care. I am pleased that my hon. Friend the Member for Leyton and Wanstead got a constructive response from Whipps Cross, but he is right to say that coverage of play services varies across the country.

Investing in our children is not just a moral mission; it is a downpayment on a better future. Children do not stop being children when they enter a hospital or a GP clinic. It is important to treat children like children when they are at home, at school or in hospital. There is growing evidence that therapeutic play can mitigate risks of trauma. We recognise that play services are integral to paediatric care, not a nice-to-have. We published the NHS England and Starlight Play Well toolkit in June last year, and I am delighted to see representatives of Starlight in the Public Gallery today. That included the first national guidelines and standards for commissioning and delivering health play services in England. NHS England is making sure that every manager of health play services knows about the Play Well toolkit across a wide range of settings. We are promoting it in community clinics, emergency departments, children’s hospices and acute paediatric wards. A range of communication channels have been used to raise awareness, including engagement with services via professional bodies, messaging via the chief nursing officer, and ongoing promotion through operational delivery networks directly to trusts and with professional groups.

The NHS is also undertaking evidence-based initiatives such as the iSupport programme, which focuses on ensuring children’s rights and wellbeing. The iSupport checklist aims to help professionals deliver safe, compassionate and child-centred care. The programme is already being picked up by children’s wards across the country. I look forward to meeting Starlight. We have been trying to get this meeting in the diary for some time, and I am delighted that we have managed to do that. I look forward to working with Starlight to see where we can go further to help kids like Hari avoid childhood trauma.

[Jen Craft]

Recently, my daughter had an in-patient stay, and I saw a Starlight notice on the door of the playroom. Having met Starlight, it gave me quite a lot of confidence. In fact, thanks to the play therapist, the most traumatic thing about my daughter’s visit was when she had to leave, as she had such a good time. That was in an inner-city hospital; we also have a regional hospital that does not have the same resources. Can the Minister say how play therapy can be rolled out across the country so that every child can benefit?

[Ashley Dalton]

As I stated earlier, we are promoting the Play Well toolkit right across the country through a variety of communication methods. We look forward to a variety of healthcare settings using that toolkit to deliver in their local areas.

That moves me on to mental health. Under this Government, all children will have access to a mental health support team in their school or college by the end of this Parliament. We are also committed to opening 50 Young Futures hubs over the next four years, which will bring together services to help young people at a community level. There have been calls for us to go further on the children’s health workforce. The Minister for Secondary Care, my hon. Friend the Member for Bristol South (Karin Smyth), is absolutely committed to making sure that we have the right skills to care for patients, including children, when they need it. We are working through the changes and what they will mean for different professional groups. I know that mental health will be at the top of the agenda, not least for children.

Health play therapists are trained through foundation degrees. The toolkit that has been developed sets out clearly how services should support practical training of specialists. Games and active play build social and emotional skills and support children’s wellbeing. We want every child to feel safe from harm and for their families to feel supported. We know that the poorest children are more likely to develop long-term illnesses. That is why it is shameful that child poverty has increased by 700,000 since 2010.

With more than 4 million children now living in poverty in the UK and 800,000 children using food banks to eat, my right hon. Friend the Chancellor took the necessary decision to fund the biggest reduction in child poverty of any Budget this century. We are expanding free school meals to half a million kids whose parents are on low incomes, and lifting hundreds of thousands out of poverty by removing the two-child benefit cap.

In addition, there is a £126 million funding boost for the family hubs and Start for Life programme this financial year. Best Start family hubs will be rolled out to every local authority from April. We have kept our manifesto promise to restrict junk food advertising targeted at children. We have announced improvements to the soft drink industry levy, and we have invested £11 million in local authorities to deploy supervised toothbrushing for three to five-year-olds in schools and nurseries in the most deprived areas of England.

On neighbourhood health, my hon. Friend the Member for Leyton and Wanstead raised an important point about multidisciplinary teams for children and young people, which should take an holistic approach to looking after children. The aim is to embed general paediatricians in primary care to give specialist paediatric advice and reduce the need for out-patient paediatric referrals. Those discussions ideally bring together wider health, social care and educational specialists. The make-up of the teams is locally determined by integrated care boards, but play specialists could absolutely be involved as part of a neighbourhood team.

[Tom Hayes]

I am pleased that the Government committed £18 million to playground investment in the Budget. Does my hon. Friend agree that we should include health play professionals in the NHS workforce plan? Would she advocate for that as part of the plan?

[Ashley Dalton]

As my hon. Friend will have noticed, I referred to the workforce plan. My hon. Friend the Minister for Secondary Care will consider all areas of the workforce and what should be included. Play specialists could be involved; their use is most appropriate in teams that give face-to-face patient care, for example when a GP and a paediatrician hold a joint clinic in a GP practice.

The majority of case discussions are held virtually, without the patient or family in attendance. There is probably less need for play specialists to support children in those circumstances, but we do encourage the use of the Play Well kit, to ensure that children’s needs are taken into consideration throughout the healthcare process. For the first time, in the recently published guidance, we require NHS providers to consider children in the roll-out of all services.

The Government are cutting waiting lists, giving children a healthier start in life and lifting half a million children out of poverty. This year—2026—will be critical, as we roll out the Best Start in Life hubs to every local authority in April, while rolling out neighbourhood health hubs and implementing the 10-year plan. The Government fundamentally believe in the importance of play. I am sure all my right hon. and hon. Friends would agree that we could do with a little bit more play in our lives, including in this place. As my hon. Friend the Member for Stroud (Dr Opher) pointed out, all play is therapeutic, and we would all benefit from a little more play. I stand ready to work with NHS England, my hon. Friend the Member for Leyton and Wanstead and Starlight to make this a decisive year for children’s health.

Question put and agreed to.